NASDAQ: NAKAKindly MD Inc Stock
$11.43+0.02 (+0.18%)
Updated Jul 17, 2025
NAKA Price
$11.43
Fair Value Price
$0.18
Market Cap
$68.83M
52 Week Low
$0.65
52 Week High
$34.77
P/E
-14.84x
P/B
45.02x
P/S
3.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.47M
Earnings
-$4.37M
Gross Margin
96.6%
Operating Margin
-163.16%
Profit Margin
-177%
Debt to Equity
0.68
Operating Cash Flow
-$4M
Beta
2.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NAKA Overview
KindlyMD, Inc. is a patient-first healthcare and healthcare data company focused on redefining value-based care and patient-centered medical services. The company leverages data analysis to deliver evidence-based, personalized solutions aimed at reducing opioid use and improving health outcomes.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NAKA's potential to beat the market
- NAKA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
A
NAKA
RankedUnranked of 42
RankedUnranked of 42
Be the first to know about important NAKA news, forecast changes, insider trades & much more!
NAKA News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NAKA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAKA ($11.43) is overvalued by 6,205.97% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NAKA ($11.43) is not significantly undervalued (6,205.97%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NAKA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NAKA due diligence checks available for Premium users.
Valuation
NAKA fair value
Fair Value of NAKA stock based on Discounted Cash Flow (DCF)
Price
$11.43
Fair Value
$0.18
Overvalued by
6,205.97%
NAKA ($11.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NAKA ($11.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NAKA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NAKA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.84x
Industry
43.2x
Market
31.25x
NAKA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
45.02x
Industry
3.94x
NAKA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAKA's financial health
Profit margin
Revenue
$579.7k
Net Income
-$1.0M
Profit Margin
-179.1%
NAKA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NAKA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.6M
Liabilities
$1.0M
Debt to equity
0.68
NAKA's short-term assets ($1.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAKA's short-term assets ($1.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAKA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$865.1k
Investing
-$173.4k
Financing
-$94.5k
NAKA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAKA vs Health Information Service Stocks
Kindly MD Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.